SecurityPYDS / Payment Data Systems, Inc. (70438S202)
President and CEOHOCH LOUIS A
IndustryFunctions Related to Depository Banking, Not Elsewhere Classified
Institutional Owners9
Institutional Shares178,779 - 1.13%
Common Stock Shares Outstanding15,859,515 shares (as of 2018-03-31)
Institutional Value$ 326,000 USD

Institutional Stock Ownership and Shareholders()

PYDS / Payment Data Systems, Inc. Institutional Ownership

Payment Data Systems, Inc. (NASDAQ:PYDS) has 9 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 178,779 shares. Largest shareholders include Vanguard Group Inc, Panagora Asset Management Inc, Investors Asset Management Of Georgia Inc /ga/ /adv, UBS Group AG, BlackRock Inc., BlackRock Fund Advisors, Deutsche Bank Ag\, Morgan Stanley, and Royal Bank Of Canada.
Payment Data Systems, Inc. (NASDAQ:PYDS) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/pyds"><img src="https://images.fintel.io/us-pyds-so.png" alt="PYDS / Payment Data Systems, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-04-11 13F-HR INVESTORS ASSET MANAGEMENT OF GEORGIA INC /GA/ /ADV 10,000 18
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 2 2 0.00 0 0
2017-02-10 13F-HR BlackRock Fund Advisors 908 908 0.00 2 2 0.00
2018-05-15 13F-HR PANAGORA ASSET MANAGEMENT INC 5,829 23,158 297.29 15 42 180.00
2018-05-15 13F-HR DEUTSCHE BANK AG\ 1,020 20 -98.04 2 0 -100.00
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 266,982 0 -100.00 670 0 -100.00
2018-05-14 13F-HR Virtu Financial LLC 21,078 0 -100.00 53 0 -100.00
2018-05-09 13F-HR BlackRock Inc. 908 908 0.00 2 2 0.00
2018-05-14 13F-HR MORGAN STANLEY 53 16 -69.81 0 0
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 1,841 0 -100.00 5 0 -100.00
2018-05-14 13F-HR Hudson Bay Capital Management LP 392,000 0 -100.00 984 0 -100.00
2018-05-15 13F-HR UBS Group AG 1,627 3,894 139.34 4 7 75.00
2018-05-09 13F-HR NORTHERN TRUST CORP 10,367 0 -100.00 26 0 -100.00
2018-05-02 13F-HR THOMPSON DAVIS & CO., INC. 5,000 0 -100.00 13 0 -100.00
2018-05-15 13F-HR VANGUARD GROUP INC 112,421 139,873 24.42 282 255 -9.57

Related Articles

HIMX: Himax Technologies Analysis and Research Report

2018-06-24 - Asif

History and Development Himax Taiwan, its predecessor, was incorporated on June 12, 2001 as a limited liability company under the laws of the ROC. On April 26, 2005, the company established Himax Technologies Limited, an exempted company with limited liability under the Cayman Islands Companies Law, as a holding company to hold the shares of Himax Taiwan in connection with its reorganization and share exchange. On October 14, 2005, Himax Taiwan became its wholly owned subsidiary through a share exchange consummated pursuant to the ROC Business Mergers and Acquisitions Law through which the company acquired all of the issued and outstanding shares of Himax Taiwan, and the company issued ordinary shares to the shareholders of Himax Taiwan. Shareholders of Himax Taiwan received one of its ordinary shares in exchange for one Himax Taiwan common share. The share exchange was unanimously approved by shareholders of Himax Taiwan on June 10, 2005 with no dissenting shareholders and by ...

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

Related News Stories

Payment Data Systems' (PYDS) CEO Louis Hoch Q1 2018 Results - Earnings Call Transcript

2018-05-16 seekingalpha
Payment Data Systems, Inc. (NASDAQ:PYDS) Q1 2018 Results Earnings Conference Call May 15, 2018 5:00 PM ET (11-0)

3Pea: Strong Guidance, Uplisting, Should Propel Shares Higher

2018-04-03 seekingalpha
Management's guidance for 2018 calls for growth to meet or exceed the growth experienced in 2017. (21-0)

Payment Data Systems' (PYDS) CEO Louis Hoch Q4 2017 Results - Earnings Call Transcript

2018-03-29 seekingalpha
Payment Data Systems, Inc. (NASDAQ:PYDS) Q4 2017 Earnings Conference Call March 29, 2018 5:00 PM ET (11-0)

CUSIP: 70438S202